Optical transparency in the cornea and retinal photoreceptor layer depends on strict vascular demarcation. This physiologic vascular zoning is compromised in corneal injury and macular degeneration. This project will elucidate the molecular signals, mediators and regulators that sustain ocular vascular compartmentalization, By focusing on the endogenous anti-angiogenic molecule, soluble VEGFR-1 (also known as sFlt-1), and its nuclear up-regulator protein Raver2, in the cornea and the subretinal space. We previously demonstrated that corneal avascularity is dependent on soluble VEGFR-1 (sFlt-1). Morpholinos (synthetic morpholine-based oligonucleotides) upregulating sFlt-1 suppressed suture-induced corneal neovascularization and laser-induced choroidal neovascularization, and improve cornea transplant survival. In exciting new studies, we have discovered that Raver2, an endogenous nuclear regulatory protein, shifts Flt-1 splicing towards the soluble sFlt-1 isoform by modulating RNA processing. This is the first described function of Raver2 and the first identified nuclear promoter of sFlt-1 production. In the retina, we found that sFlt-1 is strongly expressed by the retinal pigment epithelium (RPE) and is vital for photoreceptor avascular privilege. We will build on these findings to characterize the regulation of sFlt-1 and Raver2 in the cornea and the subretinal space. Our central hypotheses are that sFlt-1 is vital to photoreceptor avascular privilege and that Raver2 knockdown will compromise ocular vascular demarcations.
Our specific aims are: 1. To determine the molecular regulators of sFlt-1 expression in the cornea and RPE We will identify the nuclear factors that regulate sFlt-1 expression, validate their relevance in angiogenic assays in vivo and in vitro, and identify their RNA binding sequences. We will determine the mechanism of action of Raver2 and whether Pax6, a master regulator of ocular development, binds the Raver2 promoter. 2. To test the prediction that upregulation of sFlt-1 by Raver2 can improve corneal transplant survival and restore photoreceptor avascular privilege in models of AMD We will determine whether Raver2 can improve corneal transplant survival (by reducing corneal neovascularization and associated immune infiltration). Next, we will determine whether Raver2 can increase retinal sFlt-1 and inhibit laser induced choroidal neovascularization. 3. To determine whether genetic ablation of Raver2 induces corneal or choroidal neovascularization. Using available targeted conditonal ES cells (Raver2tm1e(KOMP)Wtsi),we will develop a Raver2 knockout mouse (or Raver2-lox/loxp animal if the knockout is embryonically lethal). We will assess the impact of Raver2 knockout on development of corneal avascularity and retinal vascular demarcations pre- and post-natally, determine the presence of truncated transcripts and expression kinetics of Raver2 in the knockout, and whether Raver2 knockout affects expression of anti- or pro-angiogenic factors

Public Health Relevance

Understanding the molecular basis of physiologic vascular zoning in the eye will yield insights into the mechanistic disruptions that lead to corneal and subretinal neovascularization, which account for several leading causes of blindness. This project will define the molecular mediators which control the regulation of sFlt-1 in the cornea and the subretinal space (focusing on Raver2, the first nuclear upregulator of sFlt-1 alternative splicing), establishing a cornerstone of understanding the development of vascular zoning in normal and pathological situations.

Agency
National Institute of Health (NIH)
Institute
National Eye Institute (NEI)
Type
Research Project (R01)
Project #
2R01EY017950-06
Application #
8576893
Study Section
Special Emphasis Panel (DPVS)
Program Officer
Mckie, George Ann
Project Start
2006-12-01
Project End
2017-07-31
Budget Start
2013-08-01
Budget End
2014-07-31
Support Year
6
Fiscal Year
2013
Total Cost
$372,500
Indirect Cost
$122,500
Name
University of Utah
Department
Ophthalmology
Type
Schools of Medicine
DUNS #
009095365
City
Salt Lake City
State
UT
Country
United States
Zip Code
84112
Lambert, Nathan G; ElShelmani, Hanan; Singh, Malkit K et al. (2016) Risk factors and biomarkers of age-related macular degeneration. Prog Retin Eye Res 54:64-102
Yasuma, Reo; Cicatiello, Valeria; Mizutani, Takeshi et al. (2016) Intravenous immune globulin suppresses angiogenesis in mice and humans. Signal Transduct Target Ther 1:
Bogdanovich, Sasha; Kim, Younghee; Mizutani, Takeshi et al. (2016) Human IgG1 antibodies suppress angiogenesis in a target-independent manner. Signal Transduct Target Ther 1:
Cahoon, Judd M; Rai, Ruju R; Carroll, Lara S et al. (2015) Intravitreal AAV2.COMP-Ang1 Prevents Neurovascular Degeneration in a Murine Model of Diabetic Retinopathy. Diabetes 64:4247-59
Bosco, Alejandra; Romero, Cesar O; Ambati, Balamurali K et al. (2015) In vivo dynamics of retinal microglial activation during neurodegeneration: confocal ophthalmoscopic imaging and cell morphometry in mouse glaucoma. J Vis Exp :e52731
Uehara, Hironori; Mamalis, Christina; McFadden, Molly et al. (2015) The reduction of serum soluble Flt-1 in patients with neovascular age-related macular degeneration. Am J Ophthalmol 159:92-100.e1-2
Bosco, Alejandra; Romero, Cesar O; Breen, Kevin T et al. (2015) Neurodegeneration severity can be predicted from early microglia alterations monitored in vivo in a mouse model of chronic glaucoma. Dis Model Mech 8:443-55
Das, Subrata K; Gupta, Isha; Cho, Yang Kyung et al. (2014) Vimentin knockdown decreases corneal opacity. Invest Ophthalmol Vis Sci 55:4030-40
Hirano, Yoshio; Yasuma, Tetsuhiro; Mizutani, Takeshi et al. (2014) IL-18 is not therapeutic for neovascular age-related macular degeneration. Nat Med 20:1372-5
Kim, Younghee; Tarallo, Valeria; Kerur, Nagaraj et al. (2014) DICER1/Alu RNA dysmetabolism induces Caspase-8-mediated cell death in age-related macular degeneration. Proc Natl Acad Sci U S A 111:16082-7

Showing the most recent 10 out of 32 publications